31/08/2026
Nanopore sequencing is helping clinical labs fight infectious disease in real time. Read how, across six new peer-reviewed studies, researchers are showing the potential of what's possible when nanopore sequencing moves into the clinical microbiology lab.
At Oxford University Hospitals, nanopore sequencing identified bloodstream pathogens in under 3.5 hours — up to 10 hours faster than routine diagnostics — while also flagging antimicrobial resistance data up to 20 hours earlier.
At Siriraj Hospital, Thailand, researchers used Adaptive Sampling to identify the pathogens behind culture-negative infective endocarditis within an hour of sequencing — cases where standard blood cultures had returned nothing after five days.
Across seven NHS hospitals, 16S rRNA nanopore sequencing matched or outperformed Sanger sequencing and MALDI-TOF, informing antibiotic stewardship decisions for more than half the samples tested.
In New Zealand, embedding a MinION directly in a hospital lab enabled 15 months of onsite Klebsiella pneumoniae surveillance — tracking diversity and resistance genes without waiting on outside labs.
From sepsis to hospital outbreaks, comprehensive, real-time pathogen data is reshaping what's possible in the fight against infectious disease and AMR.
Read the full roundup on our blog: https://nanoporetech.com/blog/how-could-nanopore-sequencing-in-clinical-labs-combat-infectious-disease?utm_campaign=Infectious+26&utm_content=1788213605&utm_medium=social&utm_source=facebook
Oxford Nanopore Technologies products are RUO and not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.
